Fluorescent Nanosensor Offers Rapid Way to Measure Gut Health Biomarker

By Integrative Practitioner Staff

Researchers have developed a fluorescent nanosensor that rapidly detects indole-3-propionic acid (IPA), a gut microbiome-derived metabolite increasingly recognized as a marker of intestinal inflammation. The technology could provide clinicians with a faster, more accessible way to monitor inflammatory bowel disease (IBD) and assess responses to dietary and therapeutic interventions, according to findings published in Advanced Healthcare Materials (DOI: https://doi.org/10.1002/adhm.202503434).  

IPA has emerged as a potential biomarker for gut health. Blood levels are significantly reduced in patients with active ulcerative colitis (UC) and Crohn’s disease, but measuring IPA currently relies on liquid chromatography-mass spectrometry (LC-MS), a costly, specialized technique that limits routine clinical use.  

In the study, researchers developed a dual-mode fluorescent nanosensor that rapidly distinguished blood samples from healthy individuals and patients with active UC or Crohn’s disease based on differences in IPA levels. Rather than replacing LC-MS, the researchers envision the nanosensor serving as a complementary diagnostic tool that could provide an early indication of gut microbiome disruption and inflammation before symptoms worsen. 

IPA levels are strongly influenced by diet. According to the researchers, dietary patterns rich in fiber and polyphenols, such as the Mediterranean diet, increase IPA levels, while Western dietary patterns and high intake of refined carbohydrates reduce them. Low IPA levels have also been linked to a higher risk of type 2 diabetes and nonalcoholic fatty liver disease, suggesting the sensor could have applications beyond inflammatory bowel disease. 

The researchers believe the technology could eventually help clinicians monitor treatment response, evaluate personalized nutrition strategies, and objectively assess the effects of probiotics, prebiotics, or medical diets in near real time. They plan to expand the platform into a multiplexed sensor capable of detecting multiple gut metabolites simultaneously, providing a more comprehensive picture of gut health. A newly awarded Innovation to Startup grant will support commercialization of the technology and integration of machine learning algorithms designed to improve diagnostic accuracy and generate clinically actionable gut health profiles. 

To read the full article written by Deborah Borfitz, visit Diagnostics World News.